Brokers Set Expectations for Journey Medical FY2027 Earnings

Journey Medical Co. (NASDAQ:DERM - Free Report) - Investment analysts at B. Riley reduced their FY2027 earnings per share estimates for shares of Journey Medical in a research note issued on Thursday, March 27th. B. Riley analyst K. Patel now anticipates that the company will post earnings per share of $0.31 for the year, down from their previous estimate of $0.39. The consensus estimate for Journey Medical's current full-year earnings is ($1.02) per share.

Journey Medical (NASDAQ:DERM - Get Free Report) last announced its quarterly earnings data on Wednesday, March 26th. The company reported $0.08 EPS for the quarter, beating the consensus estimate of ($0.22) by $0.30. The business had revenue of $14.30 million during the quarter, compared to analyst estimates of $14.21 million. Journey Medical had a negative return on equity of 132.10% and a negative net margin of 31.74%.

Separately, Alliance Global Partners reissued a "buy" rating on shares of Journey Medical in a research note on Thursday, March 27th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Journey Medical currently has an average rating of "Buy" and an average price target of $9.67.

Remove Ads

Journey Medical Stock Performance

DERM traded up $0.12 during midday trading on Monday, hitting $6.09. 42,844 shares of the company traded hands, compared to its average volume of 85,111. The company has a quick ratio of 1.03, a current ratio of 1.38 and a debt-to-equity ratio of 1.81. Journey Medical has a 52 week low of $3.20 and a 52 week high of $6.89. The firm has a market capitalization of $127.22 million, a PE ratio of -6.48 and a beta of 0.97. The company's 50-day moving average is $5.18 and its 200 day moving average is $5.18.

Insider Buying and Selling

In related news, CEO Claude Maraoui sold 18,147 shares of the stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $5.13, for a total value of $93,094.11. Following the transaction, the chief executive officer now owns 2,092,874 shares in the company, valued at approximately $10,736,443.62. This represents a 0.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 105,831 shares of company stock worth $536,622 in the last 90 days. 13.16% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of DERM. Kovitz Investment Group Partners LLC acquired a new stake in Journey Medical during the third quarter worth about $66,000. Cetera Investment Advisers boosted its stake in shares of Journey Medical by 21.8% in the 4th quarter. Cetera Investment Advisers now owns 13,839 shares of the company's stock valued at $54,000 after buying an additional 2,478 shares during the period. Dimensional Fund Advisors LP purchased a new stake in shares of Journey Medical in the 4th quarter valued at approximately $80,000. Citadel Advisors LLC purchased a new stake in shares of Journey Medical during the 4th quarter worth approximately $174,000. Finally, Geode Capital Management LLC grew its position in Journey Medical by 13.5% during the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company's stock worth $613,000 after purchasing an additional 12,882 shares during the last quarter. 7.25% of the stock is owned by hedge funds and other institutional investors.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.